Journal article
CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors
C Panousis, U Dhagat, KM Edwards, V Rayzman, MP Hardy, H Braley, GM Gauvreau, TR Hercus, S Smith, R Sehmi, L McMillan, M Dottore, BJ McClure, LJ Fabri, G Vairo, AF Lopez, MW Parker, AD Nash, NJ Wilson, MJ Wilson Show all
Mabs | Published : 2016
Abstract
ABSTRACT: The β common-signaling cytokines interleukin (IL)-3, granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-5 stimulate pro-inflammatory activities of haematopoietic cells via a receptor complex incorporating cytokine-specific α and shared β common (βc, CD131) receptor. Evidence from animal models and recent clinical trials demonstrate that these cytokines are critical mediators of the pathogenesis of inflammatory airway disease such as asthma. However, no therapeutic agents, other than steroids, that specifically and effectively target inflammation mediated by all 3 of these cytokines exist. We employed phage display technology to identify and optimize a novel, human mon..
View full abstractGrants
Funding Acknowledgements
We thank CSL Limited Research staff (Recombinant Proteins Group, Antibody Technologies Group, Protein Technologies Group, Analytical Biochemistry Group), Karen Howie (McMaster University) and Kay Wycherley (WEHI Antibody Facility). This research was partly undertaken on the MX2 beamline at the Australian Synchrotron, Victoria, Australia and we thank the beamline staff for their assistance. This crystallography work was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC) to M.W.P and A.F.L. and from the Australian Cancer Research Foundation to M.W.P. Funding from the Victorian Government Operational Infrastructure Support Scheme to St Vincent's Institute is acknowledged. U.D. and M.W.P. are NHMRC Post-doctoral and Research Fellows, respectively.